antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-3-4-70-76antibiotics-915Research ArticleОБЗОРЫREVIEWSВакцинопрофилактика Herpes zoster при ревматических заболеваниях: пересмотр парадигмы и новые возможностиVaccine Prophylaxis of Herpes Zoster In Rheumatic Diseases: Paradigm Revision and New Opportunitieshttps://orcid.org/0000-0002-0928-3911ГридневаГ. И.GridnevaG. I.

 Гриднева Галина Игоревна — к. м. н., научный сотрудниклаборатории коморбидных инфекций и вакцинопрофилактики

ResearcherID:AFN-9929-2022. eLIBRARY SPIN-код: 2849-5029. Scopus Author ID: 56381565500 

 Каширское шоссе, 34-А,  г. Москва, 115522.

 Galina I. Gridneva — Ph. D. in medicine

ResearcherID: AFN-9929-2022.eLIBRARY SPIN: 2849-5029. Scopus Author ID: 56381565500 

 34-A Kashirskoe highway, Moscow, 115522  

gigridneva@mail.ruhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

 Белов Борис Сергеевич — д. м. н., заведующий лабораторией коморбидных инфекций и вакцинопрофилактики

ResearcherID:ABD-2219-2020. eLIBRARY SPIN-код: 3298-4315. Scopus Author ID: 7004592537 

Каширское шоссе, 34-А,  г. Москва, 115522.

 Boris S. Belov — D. Sc. in medicine

Researcher ID: ABD-2219-2020.eLIBRARY SPIN: 3298-4315. Scopus Author ID: 7004592537 

 34-A Kashirskoe highway, Moscow, 115522  

https://orcid.org/0000-0002-1833-5357АроноваЕ. С.AronovaE. S.

 Аронова Евгения Сергеевна — к. м. н., научный сотрудниклаборатории коморбидных инфекций и вакцинопрофилактики

 Researher ID AAD-1849-2019. eLIBRARY SPIN-код: 8993-5795. Scopus Author ID 55913403200 

Каширское шоссе, 34-А,  г. Москва, 115522.

 Evgenia S. Aronova — Ph. D. in medicine

Researcher ID AAD-1849-2019.eLIBRARY SPIN: 8993-5795. Scopus Author ID 55913403200 

34-A Kashirskoe highway, Moscow, 115522  

ФБГНУ НИИ ревматологии им. В. А. НасоновойРоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation202205082022673-47076Copyright © Гриднева Г.И., Белов Б.С., Аронова Е.С., 20222022Гриднева Г.И., Белов Б.С., Аронова Е.С.Gridneva G.I., Belov B.S., Aronova E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/915Актуальность

Актуальность. Вопросы вакцинации против герпесвирусной инфекции по-прежнему важны для ревматологической практики. Данная инфекция часто развивается у пациентов, получающих иммуносупрессивное лечение, особенно ингибиторами янус-киназ (класс-специфическая нежелательная реакция) и генно-инженерными биологическими препаратами.

Цель обзора — осветить современное состояние вопроса вакцинации против Herpes zoster (HZ).

Материал и методы

Материал и методы. Проанализировано 37 печатных работ (4 отечественных, 33 зарубежных), в которых рассмотрены механизмы патогенеза и клинические особенности герпесвирусной инфекции у пациентов с иммунодефицитом, как с иммуновоспалительными ревматическими заболеваниями (ИВРЗ), так и без таковых, частота и разнообразие поствакцинальных реакций, осложнений и обострений течения ИВРЗ.

Результаты

Результаты. В настоящее время имеет место тенденция к переоценке отношения ревматологического сообщества к вакцинации против HZ, в том числе живой вакциной. Данные литературы позволяют выразить оптимизм в отношении эффективной профилактики опоясывающего лишая у больных, которым планируется назначение, в первую очередь, препаратов из группы ингибиторов янус-киназ. К преимуществам адъювантной рекомбинантной субъединичной вакцины (Shingrix®) следует отнести возможность её применения на фоне лечения антиревматическими препаратами без существенных ограничений, в том числе не откладывая инициацию необходимой терапии.

Заключение

Заключение. Публикации по проблеме вакцинации против HZ немногочисленны. Необходимо проведение тщательно контролируемых исследований по эффективности и безопасности противогерпетических вакцин с акцентом на поствакцинальное течение ИВРЗ у больных ревматологического профиля, в том числе на территории Российской Федерации.

Background

Background. The issues of vaccination against the herpesvirus infection are still important in rheumatological practice.

This infection often develops in patients receiving immunosuppressive treatment, especially Janus kinase inhibitors (a class-specific adverse reaction) and genetically engineered biologics.

The aim of this review is to highlight the current state of the issue of vaccination against Herpes zoster (HZ).

Materials and Methods

Materials and Methods. 37 publications (4 domestic, 33 foreign) were analyzed, in which the mechanisms of pathogenesis

and clinical features of herpesvirus infection in patients with immunodeficiency, both with and without immunoinflammatory rheumatic diseases (IIRD), the frequency and variety of post-vaccination reactions, complications and exacerbations of the course of IIRD were considered.

Results

Results. There is currently a trend towards reassessment of the rheumatological community's opinion about HZ vaccination, including live vaccine. Literature data allow us to express optimism regarding the effective prevention of herpes zoster in patients who plan to take drugs, primarily from the group of Janus kinase inhibitors. The advantages of the adjuvant recombinant subunit vaccine (Shingrix®) include the possibility of its use against the background of treatment with antirheumatic drugs without significant restrictions, as well as no need to postpone the initiation of the necessary therapy.

Conclusions

Conclusions. Publications on the issues of HZ vaccination are few. It is necessary to conduct carefully controlled studies on the efficacy and safety of antiherpetic vaccines with an emphasis on the post-vaccination course of IIRD in patients with rheumatological profile, including in the Russian Federation.

вакцинацияHerpes zosterревматические заболеваниягенно-инженерные биологические препаратыпоствакцинальные реакциибезопасностьvaccinationHerpes zosterrheumatic diseasesgenetically engineered biological preparationspost-vaccination reactionssecurityReferencesВакцина против ветряной оспы и опоясывающего лишая: документ по позиции ВОЗ, июнь 2014. ВОЗ. Еженедельный эпидемиологический бюллетень 20 июня 2014 года. 2014; 25: 265–288. https://www.who.int/immunization/position_papers/varicella_herpes_zoster_vaccine_pp_ru_2014.pdfVaktsina protiv vetryanoj ospy i opoyasyvajyushchego lishaya: dokument po pozi-tsii VOZ, ijyun' 2014. VOZ.Ezhenedel'nyj epidemiologicheskij bjyulleten' 20 ijyunya 2014 goda. 2014; 25: 265–288. https://www.who.int/immunization/position_papers/varicella_herpes_zoster_vaccine_pp_ru_2014.pdf (in Russian)]Steain M., Sutherland J.P., Rodriguez M. et al. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol. 2014; 88 (5): 2704–2716. doi: 10.1128/JVI.03445-13.Steain M., Sutherland J.P., Rodriguez M. et al. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol. 2014; 88 (5): 2704–2716. doi: 10.1128/JVI.03445-13.Murphy K. Janeway’s immunobiology (8th ed.). Garland Science. 2012;892.Murphy K. Janeway’s immunobiology (8th ed.). Garland Science. 2012;892.Weinberg A., Canniff J., Rouphael N. et al. Varicella-Zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017; 199 (2): 604–612. doi: 10.4049/jimmunol.1700290.Weinberg A., Canniff J., Rouphael N. et al. Varicella-Zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017; 199 (2): 604–612. doi: 10.4049/jimmunol.1700290.Johnson R.W., Alvarez-Pasquin M-J., Bijl M. et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015; 3: 10–20. doi: 10.1177/2051013615599151.Johnson R.W., Alvarez-Pasquin M-J., Bijl M. et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015; 3: 10–20. doi: 10.1177/2051013615599151.Nagel M.A., Gilden D. Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol. 2014; 27: 356–60. doi: 10.1097/WCO.0000000000000092.Nagel M.A., Gilden D. Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol. 2014; 27: 356–60. doi: 10.1097/WCO.0000000000000092.Alakloby O.M., Aljabre S.H., Randha W.A. et al.Herpes zoster in eastern Saudi Arabia: clinical presentation and management. J Drugs Dermatol. 2008; 7: 457–62.Alakloby O.M., Aljabre S.H., Randha W.A. et al.Herpes zoster in eastern Saudi Arabia: clinical presentation and management. J Drugs Dermatol. 2008; 7: 457–62.Викулов Г.Х. Иммунологические аспекты герпес вирусных инфекций. Клиническая дерматология и венерология. 2015; 5: 104–114. doi: 10.17116/klinderma2015145104-114.Vikulov G.Kh. Immunologicheskie aspekty gerpes virusnykh infektsij. Klinicheskaya dermatologiya i venerologiya. 2015; 5: 104–114. doi: 10.17116/klinderma2015145104-114. (in Russian)]Yun H., Yang S., Chen L. et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016; 68: 2328–2337. doi: 10.1002/art.39670.Yun H., Yang S., Chen L. et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016; 68: 2328–2337. doi: 10.1002/art.39670.Marra F., Parhar K., Huang B., Vadlamudi N. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis. 2020 Jan 9; 7 (1): ofaa005. doi: 10.1093/ofid/ofaa005.Marra F., Parhar K., Huang B., Vadlamudi N. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis. 2020 Jan 9; 7 (1): ofaa005. doi: 10.1093/ofid/ofaa005.Kwan A., Rayes H.A., Lazova T. et al. Herpes zoster in SLE: prevalence, incidence and risk factors. Lupus Sci Med. 2022 Jan; 9 (1): e000574. doi: 10.1136/lupus-2021-000574.Kwan A., Rayes H.A., Lazova T. et al. Herpes zoster in SLE: prevalence, incidence and risk factors. Lupus Sci Med. 2022 Jan; 9 (1): e000574. doi: 10.1136/lupus-2021-000574.Ryu H.J., Han J.O., Lee S.A. et al. Risk factors for herpes zoster in patients with rheumatic diseases: a nationwide cohort study in Korea. Rheumatology. 2021; 60 (5): 2427–2433. doi: 10.1093/rheumatology/keaa636.Ryu H.J., Han J.O., Lee S.A. et al. Risk factors for herpes zoster in patients with rheumatic diseases: a nationwide cohort study in Korea. Rheumatology. 2021; 60 (5): 2427–2433. doi: 10.1093/rheumatology/keaa636.Schub D., Assmann G., Sester U. et al. VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Arthritis Res Ther. 2018; 20 (1): 252. doi: 10.1186/s13075-018-1742-5.Schub D., Assmann G., Sester U. et al. VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Arthritis Res Ther. 2018; 20 (1): 252. doi: 10.1186/s13075-018-1742-5.Rondaan C., de Haan A., Horst G. et al. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheum. 2014; 66 (11): 3122–3128. doi: 10.1002/art.38804.Rondaan C., de Haan A., Horst G. et al. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheum. 2014; 66 (11): 3122–3128. doi: 10.1002/art.38804.Yamaguchi R., Tanaka E., Nakajima A. et al. Risk of herpes zoster in patients with rheumatoid arthritis in the biologic’s era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids. Mod Rheumatol. 202232 (3): 522–527. doi: 10.1093/mr/roab026.Yamaguchi R., Tanaka E., Nakajima A. et al. Risk of herpes zoster in patients with rheumatoid arthritis in the biologic’s era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids. Mod Rheumatol. 202232 (3): 522–527. doi: 10.1093/mr/roab026.Bechman K., Subesinghe S., Norton S. et al. A systematic review and metaanalysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Oct 1; 58 (10): 1755–1766. doi: 10.1093/rheumatology/kez087.Bechman K., Subesinghe S., Norton S. et al. A systematic review and metaanalysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Oct 1; 58 (10): 1755–1766. doi: 10.1093/rheumatology/kez087.Atzeni F., Talotta R., Nucera V. et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018; 14 (11): 945–956. doi: 10.1080/1744666X.2018.1504678.Atzeni F., Talotta R., Nucera V. et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018; 14 (11): 945–956. doi: 10.1080/1744666X.2018.1504678.Almanzar G., Kienle F., Schmalzing M. et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019; 58 (11): 2051–2060. doi: 10.1093/rheumatology/kez175.Almanzar G., Kienle F., Schmalzing M. et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019; 58 (11): 2051–2060. doi: 10.1093/rheumatology/kez175.Redeker I., Albrecht K., Kekow J. et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022; 81: 41–47. doi: 10.1136/annrheumdis-2021-220651.Redeker I., Albrecht K., Kekow J. et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022; 81: 41–47. doi: 10.1136/annrheumdis-2021-220651.Муравьев Ю.В., Гриднева Г.И. Отношение к риску возникновения опоясывающего герпеса (Herpes zoster) на фоне лечения ревматоидного артрита метотрексатом. Безопасность и риск фармакотерапии. 2014; 1 (2): 27–30.Murav'ev Jyu.V., Gridneva G.I. Otnoshenie k risku vozniknoveniya opoyasy-vajyushchego gerpesa (Herpes zoster) na fone lecheniya revmatoidnogo artrita me-totreksatom. Bezopasnost' i Risk Farmakoterapii. 2014; 1 (2): 27–30. (in Russian)]US Food and Drug Administration: Zostavax® (zoster vaccine live): high lights of prescribing information. 2019. Available at: https://www.fda.gov/media/119879/ download. Accessed 04 May 2021.US Food and Drug Administration: Zostavax® (zoster vaccine live): high lights of prescribing information. 2019. Available at: https://www.fda.gov/media/119879/ download. Accessed 04 May 2021.Us Food and Drug Administration: Shingrix: highlights of prescribing information. 2019. Available at: https://www. gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/ Shingrix/pdf/SHINGRIX.PDF. Accessed 22 June 2021Us Food and Drug Administration: Shingrix: highlights of prescribing information. 2019. Available at: https://www. gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/ Shingrix/pdf/SHINGRIX.PDF. Accessed 22 June 2021Белов Б.С., Тарасова Г.М., Муравьева Н.В. Современные подходы к вакцинации больных с ревматическими заболеваниями. Терапевтический архив. 2021; 93 (5): 622–627. doi: 10.26442/00403660. 2021.05.200794.Belov B.S., Tarasova G.M., Murav'eva N.V. Sovremennye podkhody k vaktsinatsii bol'nykh s revmaticheskimi zabolevaniyami. Terapevticheskij Arkhiv. 2021; 93 (5): 622–627. doi: 10.26442/00403660.2021.05.200794. (in Russian)]Available at: https://clinicaltrials.gov/ct2/results?cond=Persistence+of+Protection+by+Shingrix+&term=&cntry=&state=&city=&dist=/ Accessed 25 June 2021.Available at: https://clinicaltrials.gov/ct2/results?cond=Persistence+of+Protection+by+Shingrix+&term=&cntry=&state=&city=&dist=/ Accessed 25 June 2021.Tricco A.C., Zarin W., Cardoso R. et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ. 2018; 363: k4029. doi: 10.1136/bmj.k4029.Tricco A.C., Zarin W., Cardoso R. et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ. 2018; 363: k4029. doi: 10.1136/bmj.k4029.Singh J.A., Saag K.G., Bridges S.L. J.R. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016; 68: 1–26. doi: 10.1002/art.39480.Singh J.A., Saag K.G., Bridges S.L. J.R. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016; 68: 1–26. doi: 10.1002/art.39480.Choi W.S., Choi J-H., Kwon K.T. et al. Revised adult immunization guideline recommended by the Korean Society of Infectious Diseases, 2014. Infect Chemother 2015; 47: 68–79. doi: 10.3947/ic.2015.47.1.68.Choi W.S., Choi J-H., Kwon K.T. et al. Revised adult immunization guideline recommended by the Korean Society of Infectious Diseases, 2014. Infect Chemother 2015; 47: 68–79. doi: 10.3947/ic.2015.47.1.68.Choi W.S. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res. 2013; 2: 92–6. doi: 10.7774/cevr.2013.2.2.92.Choi W.S. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res. 2013; 2: 92–6. doi: 10.7774/cevr.2013.2.2.92.Curtis J.R., Cofield S.S., Bridges S.L. Jr. et al. The Safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial. Ann Intern Med. 2021; 174 (11): 1510–1518. doi: 10.7326/M20-6928.Curtis J.R., Cofield S.S., Bridges S.L. Jr. et al. The Safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial. Ann Intern Med. 2021; 174 (11): 1510–1518. doi: 10.7326/M20-6928.Baumrin E., Van Voorhees A., Garg A. et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019; 81 (1): 102–110. doi: 10.1016/j.jaad.2019.03.017.Baumrin E., Van Voorhees A., Garg A. et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019; 81 (1): 102–110. doi: 10.1016/j.jaad.2019.03.017.Papp K.A., Haraoui B., Kumar D. et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019; 23: 50–74. doi: 10.1177/1203475418811335.Papp K.A., Haraoui B., Kumar D. et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019; 23: 50–74. doi: 10.1177/1203475418811335.Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79 (1): 39–52. doi: 10.1136/annrheumdis-2019-215882.Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79 (1): 39–52. doi: 10.1136/annrheumdis-2019-215882.Winthrop K.L., Tanaka Y., Lee E.B. et al. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clin Exp Rheumatol. 2022; 40 (1): 162–172. doi:10.55563/clinexprheumatol/cpu6r9.Winthrop K.L., Tanaka Y., Lee E.B. et al. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clin Exp Rheumatol. 2022; 40 (1): 162–172. doi:10.55563/clinexprheumatol/cpu6r9.Australian Government Department Of Health: Australian Immunisation Hand book: Zoster (herpes zoster). 2018. Available at: https://immunisationhandbook.health.gov. au/vaccine-preventable-diseases/zoAustralian Government Department Of Health: Australian Immunisation Hand book: Zoster (herpes zoster). 2018. Available at: https://immunisationhandbook.health.gov. au/vaccine-preventable-diseases/zoZhang J., Delzell E., Xie F. et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011; 13:R174. doi: 10.1186/ar3497. Epub 2011 Oct 24.Zhang J., Delzell E., Xie F. et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011; 13:R174. doi: 10.1186/ar3497. Epub 2011 Oct 24.Koh J.H., Lee J., Kim S.H. et al. Safety, and humoral and cell-mediated immune responses to Herpes Zoster vaccine in patients with rheumatoid arthritis. J Rheumatol. 2018; 45 (4): 465–469. doi: 10.3899/jrheum.170936.Koh J.H., Lee J., Kim S.H. et al. Safety, and humoral and cell-mediated immune responses to Herpes Zoster vaccine in patients with rheumatoid arthritis. J Rheumatol. 2018; 45 (4): 465–469. doi: 10.3899/jrheum.170936.Stevens E., Weinblatt M., Massarotti E. et al. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center’s experience with 400 patients. ACR Open Rheumatol. 2020; 2: 357–61. doi: 10.1002/acr2.11150.Stevens E., Weinblatt M., Massarotti E. et al. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center’s experience with 400 patients. ACR Open Rheumatol. 2020; 2: 357–61. doi: 10.1002/acr2.11150.Winthrop K.l., Wouters A.G., Choy E.H. et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017; 69: 1969–77. doi: 10.1002/art.40187.Winthrop K.l., Wouters A.G., Choy E.H. et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017; 69: 1969–77. doi: 10.1002/art.40187.

The authors declare that there are no conflicts of interest present.